Brazil's AI MedTech Crackdown: Pure Global on ANVISA's New Cybersecurity Demands cover art

Brazil's AI MedTech Crackdown: Pure Global on ANVISA's New Cybersecurity Demands

Brazil's AI MedTech Crackdown: Pure Global on ANVISA's New Cybersecurity Demands

Listen for free

View show details

About this listen

 Brazil's MedTech landscape is shifting. A quiet but powerful new technical note from ANVISA has just redefined the rules for AI-powered medical devices, creating immediate hurdles for global manufacturers. This update directly links cybersecurity and data privacy to the core of the device approval process, impacting all new and pending registrations. In this episode, we dissect the three critical areas of this clarification, from new clinical data expectations to the now-mandatory Software Bill of Materials (SBOM). We explore how ANVISA is tightening its alignment with Brazil's General Data Protection Law (LGPD) and what it means for your technical dossier. This is essential listening for any innovator looking to enter or expand within Latin America's largest market. Case Study Spotlight: Imagine your cutting-edge AI diagnostic software is deep into the ANVISA review process, and your launch in Brazil seems imminent. Suddenly, your application is stalled by a list of unexpected technical questions about cybersecurity monitoring and LGPD compliance, topics your initial submission only briefly touched upon. Your team must now scramble to produce new documentation that meets these unwritten rules, delaying your market entry by months and putting you behind competitors. What’s your next move. Key Takeaways: - What are the three most critical changes in ANVISA's new interpretation of AI SaMD regulations. - How does this technical note immediately affect your pending medical device submission in Brazil. - Why has a Software Bill of Materials (SBOM) suddenly become essential for approval. - Is your current cybersecurity plan robust enough to satisfy both ANVISA and Brazil's LGPD. - What specific documentation do you need to prepare now to avoid registration delays. - How can you transform this new regulatory challenge into a powerful competitive advantage. At Pure Global, we specialize in navigating these complex and evolving regulatory landscapes. Our team of local experts in Brazil, combined with advanced AI and data tools, provides end-to-end solutions to ensure your MedTech and IVD products achieve and maintain market access. From initial regulatory strategy and dossier submission to post-market surveillance, we streamline your path into over 30 global markets. Don't let unexpected regulatory shifts derail your expansion. Contact Pure Global at info@pureglobal.com or visit https://pureglobal.com/ to secure your market presence.
No reviews yet